Bay Street News, 2024

Q1 2024 Total Revenue increased 145% Y/Y and 34% Q/Q Q1 Co-Location Business Revenue increased 90% Y/Y and 83% Q/Q […]

Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients […]

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company […]

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), the essential life […]

MARKHAM, Ontario, May 15, 2024 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for […]

IND clearance for GTB-3650, a 2ndgeneration nanobody TriKE®for treatment of CD33+ leukemia expected in Q2 2024 Phase 1 trial initiation […]

Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™ […]

• Posts Adjusted EBITDA Margin of 23.3% as a % of Revenue • Announced Normal Course Issuer Bid (“NCIB”) Subsequent to […]

LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) — NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or the “Company” or the “Group”), […]

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) —  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, […]